

Therapeutic Development Assessment (TDA) Partnership Group established 2003

The TDA Partnership Group meet regularly on a bi-monthly and as required basis to discuss improvements and monitor the implementation of the All Wales Medicines Strategy Group (AWMSG) TDA process for both AWMSG and the pharmaceutical industry. These informal meetings, between representatives of the Association of British Pharmaceutical Industry (ABPI) Wales Value Group and the All Wales Therapeutics & Toxicology Centre (AWTTC), facilitate a two-way communication channel between industry and AWTTC to inform process or methodology improvements in Wales and to share experiences of industry engagement with other Health Technology Assessment (HTA) organisations. Suggestions from these meetings are forwarded to the AWMSG Steering Committee for information and consideration.

The ABPI Wales Value Group representation comprises:

- Chair of the Wales Value Group
- A local representative of the ABPI Wales Cymru Wales Industry Group (WIG)
- Director of ABPI Cymru Wales
- Representative of EMIG (2011)
- All Wales Medicines Procurement Specialist Pharmacist (2017)
- AWTTC Representatives

Selection and Remit:

Members of the ABPI Wales Value Group are selected either because their role incorporates responsibility for HTA within their company, or because they bring knowledge and experience of the health environment in Wales. The Group further reports into a more senior level committee - the Health Technology Assessment Taskforce, within the ABPI, and ultimately to the ABPI Board of Management. Such a reporting structure enables the ABPI Wales Value Group to best represent the consolidated view and opinion of the pharmaceutical industry.

Topics at the meetings include:

Appraisal process, including a review of TDA submission forms and FAQs

- Decision making methodology
- Communication channels with industry
- Communication with the NHS, patients and the broader public arena
- Future developments of the TDA process and methodology